IRLAB Therapeutics AB (publ) Stock Price

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms of Parkinson’s disease. Its preclinical stage products include IRL942 research programs for the treatment of cognitive deficits in Parkinson’s and other neurological disorders; IRL757 to treat apathy in neurological diseases; and IRL1117, a drug candidate developed oral treatment for the hallmark symptoms of Parkinson’s. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson’s core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.